Abstract: Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds is provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated.

Abstract: The present invention is directed to human Ly6-BIG molecules and their use in diagnostic, prognostic, and treatment methods for colon, lung and other cancers, in preventing the reoccurrence of such cancers, and in diagnostic, prognostic, and treatment methods for autoimmune disorders and AIDS.

Abstract: Various embodiments are described herein for a system and method of detecting Automatic Identification System (AIS) signals in space and decoding these signals. In one aspect, a system for performing this function is described which includes a receiver configured to receive the plurality of AIS signals and pre-process the plurality of AIS signals to produce digital input data, and a processing unit configured to process the digital input data to identify one or more candidate AIS message signals based on Doppler offsets associated with the digital input data, determine corresponding Doppler offset estimates and time estimates of the one or more candidate AIS message signals, decode the one or more candidate AIS message signals to obtain corresponding message segments and validate the decoded message segments for proper AIS formatting.

Abstract: Cancer stem cell populations characterized by expression of CD44hi, ABCG2, ?-catenin, CD117, CD133, ALDH, VLA-2, CD166, CD201, IGFR, and/or EGF1R, and methods of isolating and using the same.

Abstract: Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds is provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated.

Abstract: A method of extracting automatic identification system (AIS) message segments from AIS signals received by a satellite. The method includes: (a) receiving AIS signals from satellite antennas; (b) generating multiple versions of the AIS signals; (c) extracting message segments contained within each of the AIS signals using one or more AIS receivers; (d) sorting the message segments by time; and (e) deleting any duplicate message segments. Multiple versions of the AIS signals may be generated by one or more of the following methods: (i) processing the AIS signals multiple times, each time with different AIS receiver parameter settings; (ii) splitting each signal into multiple signals and filtering each of the multiple signals separately; (iii) receiving multiple AIS signals and combining them with different phases and amplitudes to produce a plurality of combined AIS signals; and (iv) removing extracted message segments from the received AIS signals and reprocessing the modified AIS signals.

Abstract: Various embodiments are described herein for a system and method of detecting Automatic Identification System (AIS) signals in space and decoding these signals. In one aspect, a system for performing this function is described which includes a receiver configured to receive the plurality of AIS signals and pre-process the plurality of AIS signals to produce digital input data, and a processing unit configured to process the digital input data to identify one or more candidate AIS message signals based on Doppler offsets associated with the digital input data, determine corresponding Doppler offset estimates and time estimates of the one or more candidate AIS message signals, decode the one or more candidate AIS message signals to obtain corresponding message segments and validate the decoded message segments for proper AIS formatting.

Abstract: The present invention is directed to human Ly6-BIG molecules and their use in diagnostic, prognostic, and treatment methods for colon, lung and other cancers, in preventing the reoccurrence of such cancers, and in diagnostic, prognostic, and treatment methods for autoimmune disorders and AIDS.

Abstract: Various embodiments are described herein for a system and method of detecting Automatic Identification System (AIS) signals in space and decoding these signals. In one aspect, a system for performing this function is described which includes a receiver configured to receive the plurality of AIS signals and pre-process the plurality of AIS signals to produce digital input data, and a processing unit configured to process the digital input data to identify one or more candidate AIS message signals based on Doppler offsets associated with the digital input data, determine corresponding Doppler offset estimates and time estimates of the one or more candidate AIS message signals, decode the one or more candidate AIS message signals to obtain corresponding message segments and validate the decoded message segments for proper AIS formatting.

Abstract: The present invention relates to antibodies, or antigen binding fragments, variants, or derivatives thereof. In particular embodiments, the present invention relates to recombinant monoclonal antibodies, specific for mouse CD20. In addition, the present invention relates to nucleic acid molecules encoding such antibodies, or antigen binding fragments, variants, or derivatives thereof, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the monoclonal antibodies or antigen binding fragments, variants, or derivatives thereof of the invention, and to methods of using these antibodies or antigen binding fragments, variants, or derivatives thereof, alone or in combination, in animal models of disease.

Abstract: Human IGSF9 and LIV-1 polypeptides and DNA (RNA) encoding such polypeptides are disclosed. The disclosed polypeptides and/or polynucleotide are particularly useful generating antibodies, both modified and native, which bind IGSF9 or LIV-1. Also disclosed are pharmaceutical compositions and vaccines comprising the antibodies, polypeptides and polynucleotides of the invention. Also disclosed are methods for utilizing such polypeptides for identifying ligands, antagonists and agonists to said polypeptides. Finally, methods comprising the above-mentioned compositions are disclosed for the treatment, diagnosis, and/or prognosis of neoplastic disorders.

Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.

Abstract: The present invention is directed to novel methods of treating or diagnosing a hyperproliferative disease or disorder in an patient, where the methods include administrating to the patient a binding molecule which binds to a cell surface-expressed glycoprotein expressed predominantly in tumor or tumor-associated cells. In particular, the therapeutic and diagnostic methods of the present invention include the use of a binding molecule, for example an antibody or immunospecific fragment thereof, which specifically binds to the human LRRC15 protein. The present invention further provides a method of isolating and identifying cell surface expressed glycoproteins expressed in tumor or tumor associated tissues, where the method includes isolating desired glycoproteins via their affinity for specific lectins.

Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.

Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.

Abstract: A system and method of calibrating an S parameter measurement instrument (such as a vector network analyzer) in which the number of calibrations required to fully characterize the error model of an n-port system is n/2 calibrations for an even number of ports and (n+1)/2 calibrations for an odd number of ports. Each test port in the system is involved in at least one full calibration, thus n/2 test paths are fully calibrated. For each measured test path, the error terms of the applicable error model are calculated. These error terms are then decoupled from the associated test path into error parameters that are localized to the individual test ports of the test path. Having localized the error parameters, the error model for each test port can then be treated independently from the other test ports. The error terms for the test paths that are not calibrated are then constructed using the localized error parameters for the individual test ports.

Abstract: The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins including CTLA4/CD28 chimeric proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.

Abstract: An improved multi-beam bent-pipe communications satellite system and method includes a subchannel switching processor for extracting and switching subchannels of information to and from a plurality of uplink and downlink beams and an intersatellite link for routing certain of the extracted subchannels to another satellite in the system. The subchannel switching processor preferably employs a partial subchannelization processor that combines a coaxial switching network for switching some of the uplink channels at the channel level with an analog or digital transparent subchannel switching network connected to a portion of the uplink channels for extracting and switching at the subchannel level. The switched subchannels are combined to form channels, and then routed to either the downlink beams (where they are combined with other switched channels), or to the intersatellite link for transmission to another satellite.

Abstract: A repeater for a multibeam communications satellite combines the features of coaxial channel interbeam switching and subchannelization of some of the channels. In one embodiment described, the input radio-frequency signals from the input beams are fed through the input multiplexers to form channels. Some, but not all, channels are subsequently subchannelized for interbeam switching. In another embodiment of the invention, a portion of the incoming radio frequency signals bypasses the input demultiplexer and is filtered for noise-limiting reasons, converted down to an intermediate frequency and then subchannelized using SAW filters. The specification also teaches that digital techniques can be used to obtain the same results.

Abstract: The invention provides CTLA4 mutant molecules as ligands for the B7 antigen. Methods are provided for expressing CTLA4 mutant molecules as soluble, functional molecules, for preparing CTLA4 mutant fusion proteins, and for using these soluble molecules to regulate T cell interactions and immune responses mediated by such interactions.